{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:30:36Z","timestamp":1792668636050,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T00:00:00Z","timestamp":1323993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Improved outcomes have recently been reported for rituximab (R) plus rituximab plus infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R\u2010EPOCH) chemotherapy in patients with human immunodeficiency virus (HIV)\u2010associated, aggressive B\u2010cell, non\u2010Hodgkin lymphoma (NHL). The objective of the current analysis was to assess whether patient selection or other factors contributed to this improvement and to identify patients who are at the greatest risk for lethal toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors performed a pooled analysis of 2 consecutive trials that included 150 patients with HIV\u2010associated NHL who received either R\u2010CHOP (n = 99; Acquired Immunodeficiency Syndrome [AIDS] Malignancy Consortium Trial 010 [AMC010]) or R\u2010EPOCH (n = 51; AMC034). Age\u2010adjusted International Prognostic Index (aaIPI), CD4 count at lymphoma diagnosis (&lt;100\/\u03bcL vs \u2265100\/\u03bcL), and treatment (R\u2010CHOP vs R\u2010EPOCH) were included as variables in a multivariate logistic regression model for complete response (CR) and in a Cox proportional hazards regression models for event\u2010free survival (EFS) and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Features that were associated significantly with an improved CR rate and improved EFS and OS included a low aaIPI score and a baseline CD4 count \u2265100\/\u03bcL. When the analysis was adjusted for aaIPI and CD4 count, patients who received concurrent R\u2010EPOCH had improved EFS (hazard ratio [HR] 0.40; 95% confidence intervals [CI], 0.23, 0.69; <jats:italic>P<\/jats:italic> &lt; .001) and OS (HR, 0.38; 95% CI, 0.21, 0.69; <jats:italic>P<\/jats:italic> &lt; .01). Treatment\u2010associated death occurred significantly more often in patients with CD4 counts &lt;50\/\u03bcL (37% vs 6%; <jats:italic>P<\/jats:italic> &lt; .01).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The current analysis provided additional level 2 evidence supporting the use of concurrent R\u2010EPOCH in patients with HIV\u2010associated lymphoma and a CD4 count &gt;50\/\u03bcL, and the results support the design of an ongoing phase 3 trial comparing concurrent R\u2010EPOCH with R\u2010CHOP in immunocompetent patients with diffuse large B\u2010cell lymphoma (National Clinical Trial no. NCT00118209). Cancer 2012. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26723","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T10:41:18Z","timestamp":1324032078000},"page":"3977-3983","source":"Crossref","is-referenced-by-count":97,"title":["Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV\u2010associated non\u2010Hodgkin lymphoma"],"prefix":"10.1002","volume":"118","author":[{"given":"Stefan K.","family":"Barta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence D.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1462"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.4.416"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f47082"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a0961"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.003"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4684"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06943.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-262717"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.5.1634.h81702001634_1634_1640"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.195"},{"key":"e_1_2_6_19_2","article-title":"Long\u2010term outcome of AIDS\u2010related lymphoma treated with abbreviated cycles of EPOCH\u2010RR: a prospective study of 40 patients","volume":"112","author":"Dunleavy K","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231613"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3589"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-4-S2-O9"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253039"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2391::AID-CNCR29>3.0.CO;2-0"},{"key":"e_1_2_6_27_2","first-page":"508","article-title":"International Prognostic Index is the best prognostic factor for survival in patients with AIDS\u2010related non\u2010Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients","volume":"83","author":"Navarro J","year":"1998","journal-title":"Haematologica."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.9355"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3601"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2217"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-4-200508160-00007"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26723","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:09:22Z","timestamp":1760281762000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,16]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,8,15]]}},"alternative-id":["10.1002\/cncr.26723"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26723","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,16]]}}}